RxDoctor Payments Data

Natasha Maguire, APRN

Nurse Practitioner · Ocala, FLNPI 1477011062

Payments from drug & device makers

$7,061in general payments, 2019–2025

Across 395 payments — averaging $17.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Eisai Inc.$844
  • Teva Pharmaceuticals USA, Inc.$823
  • Neurocrine Biosciences, Inc.$580
  • Acadia Pharmaceuticals Inc$499
  • MDD US Operations, LLC$427
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$7,01799%
  • Education$451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,061 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$11,015
Medicare patients
50
Services billed
868

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate63$353,424
RytaryCarbidopa/Levodopa31$91,341
RexultiBrexpiprazole23$57,141
NeuproRotigotine21$28,120
Memantine Hcl455$12,584
Carbidopa-LevodopaCarbidopa/Levodopa319$11,364
Rivastigmine39$6,623
Carbidopa-Levodopa ErCarbidopa/Levodopa134$5,619
AmantadineAmantadine Hcl62$4,818
Pramipexole DihydrochloridePramipexole Di-Hcl94$4,081
Duloxetine Hcl72$3,617
Rasagiline Mesylate17$3,027
Memantine Hcl ErMemantine Hcl23$2,616
Quetiapine Fumarate136$2,079
Entacapone14$1,755

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$499$353,42463 claims
Amneal Pharmaceuticals LLCRytary$410$91,34131 claims
Otsuka America Pharmaceutical, Inc.Rexulti$424$57,14123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →